ID
34260
Beschrijving
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01511874
Link
https://clinicaltrials.gov/show/NCT01511874
Trefwoorden
Versies (1)
- 16-01-19 16-01-19 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
16 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Prostate Cancer NCT01511874
Eligibility Prostate Cancer NCT01511874
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
Hormone refractory prostate cancer
Datatype
boolean
Alias
- UMLS CUI [1]
- C1328504
Beschrijving
Metastatic malignant neoplasm to brain
Datatype
boolean
Alias
- UMLS CUI [1]
- C0220650
Beschrijving
Primary tumor Other | Exception Prostate carcinoma
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0677930
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [2,1]
- C1705847
- UMLS CUI [2,2]
- C0600139
Beschrijving
Condition Study Subject Participation Status Excluded
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0348080
- UMLS CUI [1,2]
- C2348568
- UMLS CUI [1,3]
- C0332196
Similar models
Eligibility Prostate Cancer NCT01511874
- StudyEvent: Eligibility
C0001779 (UMLS CUI [2])
C0474935 (UMLS CUI [1,2])
C0002594 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C1520224 (UMLS CUI [2])
C0205394 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])